Year: 2014
Type: review
Abstract: The identification of tau protein as a major constituent of neurofibrillary tangles spurred considerable effort devoted to identifying and validating pathways through which therapeutics may alleviate tau burden in Alzheimer's disease and related tauopathies, including chronic traumatic encephalopathy associated with sport- and military-related injuries. Most tau-based therapeutic strategies have previously focused on modulating tau phosphorylation, given that tau species present within neurofibrillary tangles are hyperphosphorylated on a number of different residues. However, the recent discovery that tau is modified by acetylation necessitates additional research to provide greater mechanistic insight into the spectrum of physiological consequences of tau acetylation, which may hold promise as a novel therapeutic target. In this review, we discuss recent findings evaluating tau acetylation in the context of previously accepted notions regarding tau biology and pathophysiology. We also examine the evidence demonstrating the neuroprotective and beneficial consequences of inhibiting histone deacetylase (HDAC)6, a tau deacetylase, including its effect on microtubule stabilization. We also discuss the rationale for pharmacologically modulating HDAC6 in tau-based pathologies as a novel therapeutic strategy.
Source: Alzheimer s Research & Therapy
DOI: 10.1186/alzrt259
Institution: Mayo Clinic in Florida
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,290
Awards: TDP-43, RNA Metabolism, and ALS/FTD Pathology, Misregulation of the TDP-43 RNA target, Sortilin, in neurodegeneration, HDAC6 and Tau Pathobiology, Development and Testing of Hsp90 Inhibitors, G4700852728, Tau and Neurodegeneration II: A therapeutic target, Progranulin, TDP-43 and Cell Death, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W2107339320
